Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma

被引:1
作者
Wong, Lye-Yeng [1 ]
Liou, Douglas Z. Z. [1 ]
Vitzthum, Lucas K. K. [2 ]
Backhus, Leah M. M. [1 ,3 ]
Lui, Natalie S. S. [1 ]
Chang, Daniel [2 ]
Shrager, Joseph B. B. [1 ,3 ]
Berry, Mark F. F. [1 ,3 ]
机构
[1] Stanford Univ, Falk Cardiovasc Res Inst, Dept Cardiothorac Surg, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Radiat Oncol, Stanford, CA USA
[3] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
关键词
CHEMORADIOTHERAPY PLUS SURGERY; SALVAGE ESOPHAGECTOMY; CANCER; EPIDEMIOLOGY; SURVEILLANCE; CHEMOTHERAPY; RADIOTHERAPY; PERSISTENT; RESECTION; SURVIVAL;
D O I
10.1245/s10434-022-12980-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Performing selective esophagectomy for locally advanced squamous cell carcinoma may spare patients morbidity, but delayed surgery may infer higher risks. This study evaluated the impact of length of time between chemoradiation and esophagectomy on perioperative outcomes and long-term survival. Methods. The impact of surgical timing, stratified by surgery performed < 180 and >= 180 days from starting radiation, on perioperative outcomes and survival in patients treated with chemoradiation and esophagectomy for cT1N + M0 and cT2-4, any N, M0 squamous cell carcinoma of the mid-distal esophagus in the National Cancer Database (2006-2016) was evaluated with logistic regression, Kaplan-Meier curves, Cox proportional-hazards methods, and propensity-matched analysis. Results. Median time between starting radiation and esophagectomy in 1641 patients was 93 (IQR 81-114) days. Most patients (96.8%, n = 1589) had surgery within 180 days of starting radiation, while 52 patients (3.2%) had delayed surgery. Black race and clinical T stage were associated with delayed surgery. Rates of pathologic upstaging, downstaging, complete response, and positive margins were not significantly different between the groups. Patients with delayed surgery had increased major morbidity as measured by a composite of length of hospital stay, readmission, and 30-day mortality [42.3% (22/52) vs 22.3% (355/1589), p = 0.001]. However, delayed surgery was not associated with a significant difference in survival in both univariate [5-year survival 32.8% (95% CI 21.1-50.7) vs 47.3% (44.7-50.1), p = 0.19] and multivariable analysis [hazard ratio (HR) 1.23 (0.85-1.78), p = 0.26]. Conclusions. Delaying surgery longer than 180 days after starting chemoradiation for esophageal squamous cell carcinoma is associated with worse perioperative outcomes but not long-term survival.
引用
收藏
页码:2212 / 2223
页数:12
相关论文
共 38 条
  • [1] Esophagectomy Compared With Chemoradiation for Early Stage Esophageal Cancer in the Elderly
    Abrams, Julian A.
    Buono, Donna L.
    Strauss, Joshua
    McBride, Russell B.
    Hershman, Dawn L.
    Neugut, Alfred I.
    [J]. CANCER, 2009, 115 (21) : 4924 - 4933
  • [2] Esophageal and Esophagogastric Junction Cancers, Version 2.2019
    Ajani, Jaffer A.
    D'Amico, Thomas A.
    Bentrem, David J.
    Chao, Joseph
    Corvera, Carlos
    Das, Prajnan
    Denlinger, Crystal S.
    Enzinger, Peter C.
    Fanta, Paul
    Farjah, Farhood
    Gerdes, Hans
    Gibson, Michael
    Glasgow, Robert E.
    Hayman, James A.
    Hochwald, Steven
    Hofstetter, Wayne L.
    Ilson, David H.
    Jaroszewski, Dawn
    Johung, Kimberly L.
    Keswani, Rajesh N.
    Kleinberg, Lawrence R.
    Leong, Stephen
    Ly, Quan P.
    Matkowskyj, Kristina A.
    McNamara, Michael
    Mulcahy, Mary F.
    Paluri, Ravi K.
    Park, Haeseong
    Perry, Kyle A.
    Pimiento, Jose
    Poultsides, George A.
    Roses, Robert
    Strong, Vivian E.
    Wiesner, Georgia
    Willett, Christopher G.
    Wright, Cameron D.
    McMillian, Nicole R.
    Pluchino, Lenora A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (07): : 855 - 883
  • [3] Global incidence of oesophageal cancer by histological subtype in 2012
    Arnold, Melina
    Soerjomataram, Isabelle
    Ferlay, Jacques
    Forman, David
    [J]. GUT, 2015, 64 (03) : 381 - 387
  • [4] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma
    Barbetta, Arianna
    Hsu, Meier
    Tan, Kay See
    Stefanova, Dessislava
    Herman, Koby
    Adusumilli, Prasad S.
    Bains, Manjit S.
    Bott, Matthew J.
    Isbell, James M.
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    Park, Bernard J.
    Wu, Abraham J.
    Jones, David R.
    Molena, Daniela
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06) : 2710 - 2719
  • [5] Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
  • [6] Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
    Burmeister, BH
    Smithers, BM
    Gebski, V
    Fitzgerald, L
    Simes, RJ
    Devitt, P
    Ackland, S
    Gotley, DC
    Joseph, D
    Millar, J
    North, J
    Walpole, ET
    Denham, JW
    [J]. LANCET ONCOLOGY, 2005, 6 (09) : 659 - 668
  • [7] Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?
    Castoro, Carlo
    Scarpa, Marco
    Cagol, Matteo
    Alfieri, Rita
    Ruol, Alberto
    Cavallin, Francesco
    Michieletto, Silvia
    Zanchettin, Giampietro
    Chiarion-Sileni, Vanna
    Corti, Luigi
    Ancona, Ermanno
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2013, 17 (08) : 1375 - 1381
  • [8] Medical progress - Esophageal cancer
    Enzinger, PC
    Mayer, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (23) : 2241 - 2252
  • [9] Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
    Eyck, Ben M.
    van Lanschot, J. Jan B.
    Hulshof, Maarten C. C. M.
    van der Wilk, Berend J.
    Shapiro, Joel
    van Hagen, Pieter
    Henegouwen, Mark I. van Berge
    Wijnhoven, Bas P. L.
    van Laarhoven, Hanneke W. M.
    Nieuwenhuijzen, Grard A. P.
    Hospers, Geke A. P.
    Bonenkamp, Johannes J.
    Cuesta, Miguel A.
    Blaisse, Reinoud J. B.
    Busch, Olivier R.
    Creemers, Geert-Jan M.
    Punt, Cornelis J. A.
    Plukker, John Th M.
    Verheul, Henk M. W.
    Bilgen, Ernst J. Spillenaar
    van der Sangen, Maurice J. C.
    Rozema, Tom
    Ten Kate, Fiebo J. W.
    Beukema, Jannet C.
    Piet, Anna H. M.
    van Rij, Caroline M.
    Reinders, Janny G.
    Tilanus, Hugo W.
    Steyerberg, Ewout W.
    van der Gaast, Ate
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 1995 - +
  • [10] Howlader N., 2019, SEER CANC STAT REV 1